IRISH

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Wednesday, September 27, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Wednesday, September 27, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Runa Capital II (GP) (“Runa”) Further statement re possible offer for MariaDB plc (“MariaDB” or the “Company”) Increased proposal to provide up to US$20 million in bridge financing

Retrieved on: 
Wednesday, September 27, 2023
MAKE, ACT, FOR, MariaDB, Central Bank of Ireland, A (Cyrillic), Davy, EIB, Runa Capital, The Takeover Panel, Letter, OR, Open position, FIRM, Knowledge, Disclosure, Irish Takeover Panel, NOT, Commitment, Documentation, Investment banking, Fund, Central bank, Person, MADE, Nature, ANY, IRISH, Holding company, Bank, Security (finance), Lease, Property management, Note

Dublin, Ireland, Sept. 26, 2023 (GLOBE NEWSWIRE) --  On 15 September 2023, Runa announced that it made an all cash proposal to the directors of MariaDB (the “Board”) to acquire, together with Runa’s investment affiliates, 100% of the issued share capital of the Company not already owned by Runa, at a price of US$0.56 per share (the “Possible Offer”). In that announcement, Runa noted the impending default of the Company under its senior debt and indicated that it was prepared, as an interim measure, to extend to the Company a US$5 million bridge loan on terms to be agreed between the parties.

Key Points: 
  • The Commitment Letter and its terms will expire if not fully executed by the Company on or prior to 29 September 2023.
  • In addition, the Company will pay Runa an origination fee of 0.5% of the loan amount.
  • This announcement does not constitute an offer to sell or invitation to purchase any securities.
  • Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel's website.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Tuesday, September 26, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Monday, September 25, 2023
General Health, Professional Services, Health, Finance, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Monday, September 25, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Monday, September 25, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Monday, September 25, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Monday, September 25, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Monday, September 25, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.